Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.
Noninvasive imaging methodologies are needed to assess treatment responses to novel molecular targeting approaches for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Computer tomography and magnetic resonance imaging do not effectively distinguish tumors from fibrotic tissue commonly associated with SCCHN tumors. Positron emission tomography (PET) offers functional non-invasive imaging of tumors. We determined the uptake of the PET tracers 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-[(18)F]Fluoro-3'-deoxythymidine ([(18)F]FLT) in several SCCHN xenograft models. In addition, we evaluated the utility of [(18)F]FLT microPET imaging in monitoring treatment response to an EGFR antisense approach targeted therapy that has shown safety and efficacy in a phase I trial. Two of the 3 SCCHN xenograft models tested demonstrated no appreciable uptake or retention of [(18)F]FDG, but consistent accumulation of [(18)F]FLT. The third tumor xenograft SCCHN model (Cal33) demonstrated variable uptake of both tracers. SCCHN xenografts (1483) treated with EGFR antisense gene therapy decreased tumor volumes in 4/6 mice. Reduced uptake of [(18)F]FLT was observed in tumors that responded to epidermal growth factor antisense (EGFRAS) gene therapy compared to non-responding tumors or tumors treated with control sense plasmid DNA. These findings indicate that [(18)F]FLT PET imaging may be useful in monitoring SCCHN response to molecular targeted therapies, while [(18)F]FDG uptake in SCCHN xenografts may not be reflective of the level of metabolic activity characteristic of human SCCHN tumors.
Departments of Radiology, University of Pittsburgh and University of Pittsburgh Cancer Institute Pittsburgh, PA, USA.
Neale S
NS
Mason
Brian J
BJ
Lopresti
James
J
Ruszkiewicz
Xinxin
X
Dong
Sonali
S
Joyce
George
G
Leef
Malabika
M
Sen
Abdus S
AS
Wahed
Chester A
CA
Mathis
Jennifer R
JR
Grandis
Sufi M
SM
Thomas
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG); 3’-[18F]Fluoro-3’-deoxythymidine ([18F]FLT); Squamous cell carcinoma of the head and neck (SCCHN); epidermal growth factor receptor (EGFR); positron emission tomography (PET); region of interest (ROI); standardize uptake values (SUV); volume of interest (VOI)